<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01498159</url>
  </required_header>
  <id_info>
    <org_study_id>2011-0099</org_study_id>
    <secondary_id>R01DK091347</secondary_id>
    <nct_id>NCT01498159</nct_id>
  </id_info>
  <brief_title>Health Promoters and Pharmacists in Diabetes Team Management</brief_title>
  <official_title>Health Promoters and Pharmacists in Diabetes Team Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research evaluates a diabetes management intervention designed to improve medication&#xD;
      adherence and intensify therapy to reach goals in blood sugar, blood pressure, and&#xD;
      cholesterol levels. This study will determine the benefit and cost of adding community health&#xD;
      promoters to pharmacist disease management services. If there is benefit, then this approach&#xD;
      may help reduce the burden of diabetes and its related complications among minorities with&#xD;
      diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many African-Americans and Latinos with diabetes do not achieve the recommended goals for&#xD;
      normal blood sugar, blood pressure, or cholesterol level, placing them at high risk for&#xD;
      complications. This study will evaluate the impact of a novel intervention designed to&#xD;
      improve lifestyle behaviors and medication adherence, and intensify therapy to reach goals.&#xD;
      The first component of the intervention includes a clinic-based pharmacist disease management&#xD;
      program. The program includes detailed patient assessments, physician-approved treatment&#xD;
      plans, patient education and support services to enhance medication adherence. In addition,&#xD;
      this program includes intensification of medication therapy to improve blood sugar, blood&#xD;
      pressure, and cholesterol levels to reach recommended goals. The second component of the&#xD;
      intervention includes health promoters (HPs), or community-based lay health workers. Health&#xD;
      promoters are commonly found in minority communities and provide assistance for individuals&#xD;
      overcoming language, cultural, and other barriers to conventional health care services. They&#xD;
      may provide autonomy support and solve problems related to medication adherence barriers.&#xD;
      Furthermore, health promoters may complement pharmacist activities by improving access to&#xD;
      medications, assisting in continuity of care with providers, monitoring response to therapy,&#xD;
      and reinforcing educational messages. The proposed study will determine whether the addition&#xD;
      of health promoters to clinic based pharmacist service delivery improves care. The study will&#xD;
      involve the recruitment of 300 African-American and Latino adults with uncontrolled diabetes&#xD;
      through the University of Illinois Medical Center in Chicago and randomization to one of two&#xD;
      groups: (1) pharmacist management (Pharm) for 12 months; or (2) pharmacist management with HP&#xD;
      support (Pharm+HP) for 12 months. Cross-over will occur at 12 months such that the Pharm&#xD;
      group will be intensified by the addition of HP support and HP support will be phased out&#xD;
      from the Pharm+HP group to assess maintenance. The specific aims include: (1) To evaluate the&#xD;
      effectiveness of Pharm+HP compared with Pharm alone on diabetes behaviors (including healthy&#xD;
      eating, physical activity, and medication adherence), hemoglobin A1c, blood pressure, and&#xD;
      LDL-cholesterol levels; (2) To evaluate the maintenance of improved diabetes behaviors as&#xD;
      well as clinical outcomes by phasing out HP support from the Pharm+HP group after year 1; (3)&#xD;
      To evaluate the intensification offered by adding an HP after one year of Pharm alone; and&#xD;
      (4) To evaluate the cost and cost-effectiveness of Pharm+HP and Pharm alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>24 months</time_frame>
    <description>Hemoglobin A1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diabetes Knowledge</measure>
    <time_frame>24 months</time_frame>
    <description>Diabetes Knowledge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomous Self-Regulation</measure>
    <time_frame>24 months</time_frame>
    <description>Autonomous Self-Regulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived Competence</measure>
    <time_frame>24 months</time_frame>
    <description>Perceived Competence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>24 months</time_frame>
    <description>Medication Adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>24 months</time_frame>
    <description>Body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Self-Care Behaviors</measure>
    <time_frame>24 months</time_frame>
    <description>Diabetes Self-Care Behaviors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Utilization</measure>
    <time_frame>24 months</time_frame>
    <description>Healthcare Utilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>24 months</time_frame>
    <description>Systolic Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>24 months</time_frame>
    <description>Diastolic Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>24 months</time_frame>
    <description>LDL Cholesterol</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Pharmacist + Health Promoter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive support from both a pharmacist and health promoter. Number of sessions will be determined by the study team member and patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive support from pharmacist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pharmacist disease/medication management</intervention_name>
    <arm_group_label>Pharmacist</arm_group_label>
    <arm_group_label>Pharmacist + Health Promoter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pharmacist-patient encounters</intervention_name>
    <arm_group_label>Pharmacist</arm_group_label>
    <arm_group_label>Pharmacist + Health Promoter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pharmacist medication intensification and adherence support</intervention_name>
    <arm_group_label>Pharmacist</arm_group_label>
    <arm_group_label>Pharmacist + Health Promoter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pharmacist communication with primary care physicians</intervention_name>
    <arm_group_label>Pharmacist</arm_group_label>
    <arm_group_label>Pharmacist + Health Promoter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pharmacist documentation in electronic medical record</intervention_name>
    <arm_group_label>Pharmacist</arm_group_label>
    <arm_group_label>Pharmacist + Health Promoter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Health promoter-patient encounters in-person or by phone</intervention_name>
    <arm_group_label>Pharmacist + Health Promoter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Health promoter medication and lifestyle support</intervention_name>
    <arm_group_label>Pharmacist + Health Promoter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Health promoter communication with pharmacists</intervention_name>
    <arm_group_label>Pharmacist + Health Promoter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Self-identified as Latino/Hispanic or African-American&#xD;
&#xD;
          -  Verbal fluency in English or Spanish&#xD;
&#xD;
          -  Age 21 or above&#xD;
&#xD;
          -  History of type 2 diabetes (&gt; 1 year)&#xD;
&#xD;
          -  Hemoglobin A1c ≥ 8.0% (within 1 year)&#xD;
&#xD;
          -  Receives primary care at UIMC (&gt; 1 year)&#xD;
&#xD;
          -  Taking at least one oral medication for diabetes or hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to verbalize comprehension of study or impaired decision making (e.g.,&#xD;
             dementia)&#xD;
&#xD;
          -  Lives outside Chicago communities of recruitment (3+ months/year)&#xD;
&#xD;
          -  Household member already participating in same study&#xD;
&#xD;
          -  Plans to move from the Chicago area within the next year&#xD;
&#xD;
          -  Pregnant or trying to get pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ben S Gerber, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa K Sharp, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ihrp.uic.edu/study/health-promoters-and-pharmacists-diabetes-team-management</url>
    <description>IHRP Study Description</description>
  </link>
  <reference>
    <citation>Gerber BS, Cano AI, Caceres ML, Smith DE, Wilken LA, Michaud JB, Ruggiero LA, Sharp LK. A pharmacist and health promoter team to improve medication adherence among Latinos with diabetes. Ann Pharmacother. 2010 Jan;44(1):70-9. doi: 10.1345/aph.1M389. Epub 2009 Dec 22.</citation>
    <PMID>20028957</PMID>
  </reference>
  <reference>
    <citation>Gerber BS, Rapacki L, Castillo A, Tilton J, Touchette DR, Mihailescu D, Berbaum ML, Sharp LK. Design of a trial to evaluate the impact of clinical pharmacists and community health promoters working with African-Americans and Latinos with diabetes. BMC Public Health. 2012 Oct 23;12:891. doi: 10.1186/1471-2458-12-891.</citation>
    <PMID>23088168</PMID>
  </reference>
  <results_reference>
    <citation>Sharp LK, Tilton JJ, Touchette DR, Xia Y, Mihailescu D, Berbaum ML, Gerber BS. Community Health Workers Supporting Clinical Pharmacists in Diabetes Management: A Randomized Controlled Trial. Pharmacotherapy. 2018 Jan;38(1):58-68. doi: 10.1002/phar.2058. Epub 2017 Nov 30.</citation>
    <PMID>29121408</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2011</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Ben Gerber</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Pharmacists</keyword>
  <keyword>Community Health Aides</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

